Pharmaceutical firm Cipla's second quarter profit is seen falling 13.4 percent year-on-year to Rs 373.34 crore on dismal operational performance. However, revenue may increase 9 percent to Rs 3,763.2 crore compared with year-ago period, according to average of estimates of analysts polled by CNBC-TV18.
Domestic business contributes 40 percent to sales and the rest is export.
The growth in revenue growth is likely on account of low base in Q2FY16 & consolidation of Invagen (recent US acquisition) sales. Export formulations are likely to grow around 12-14 percent to around Rs 2,050-2,100 crore in September quarter.
Domestic business may grow around 12-14 percent to over Rs 1,400 crore YoY, driven by respiratory segment growth. Export API sales may be muted with a 3-4 percent growth YoY.
Operating profit is likely to decline 16.1 percent year-on-year to Rs 662.3 crore and margin may shrink 527 basis points to 17.6 percent in Q2 due to lower Nexium sales.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
